1. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014) Authors: Reckamp, Karen L.; Giaccone, Giuseppe; Camidge, D. Ross; Gadgeel, Shirish M.; Khuri, Fadlo R.; Engelman, Jeff A.; Koczywas, Marianna; Rajan, Arun; Campbell, Alicyn K.; Gernhardt, Diana; Ruiz‐Garcia, Ana; Letrent, Stephen; Liang, Jane; Taylor, Ian; O'Connell, Joseph P.; Jänne, Pasi A. Journal: Cancer Issue: Volume 120:Issue 8(2014) Page Start: 1145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014) Authors: Reckamp, Karen L.; Giaccone, Giuseppe; Camidge, D. Ross; Gadgeel, Shirish M.; Khuri, Fadlo R.; Engelman, Jeff A.; Koczywas, Marianna; Rajan, Arun; Campbell, Alicyn K.; Gernhardt, Diana; Ruiz‐Garcia, Ana; Letrent, Stephen; Liang, Jane; Taylor, Ian; O'Connell, Joseph P.; Jänne, Pasi A. Journal: Cancer Issue: Volume 120:Issue 8(2014) Page Start: 1145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Antibody drug conjugates in thoracic malignancies. (October 2018) Authors: Pacheco, Jose M.; Camidge, D. Ross Journal: Lung cancer Issue: Volume 124(2018) Page Start: 260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Issue 3 (1st October 2014) Authors: Villaruz, Liza C.; Socinski, Mark A.; Abberbock, Shira; Berry, Lynne D.; Johnson, Bruce E.; Kwiatkowski, David J.; Iafrate, A. John; Varella‐Garcia, Marileila; Franklin, Wilbur A.; Camidge, D. Ross; Sequist, Lecia V.; Haura, Eric B.; Ladanyi, Mark; Kurland, Brenda F.; Kugler, Kelly; Minna, John D... Journal: Cancer Issue: Volume 121:Issue 3(2015) Page Start: 448 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Issue 3 (1st October 2014) Authors: Villaruz, Liza C.; Socinski, Mark A.; Abberbock, Shira; Berry, Lynne D.; Johnson, Bruce E.; Kwiatkowski, David J.; Iafrate, A. John; Varella‐Garcia, Marileila; Franklin, Wilbur A.; Camidge, D. Ross; Sequist, Lecia V.; Haura, Eric B.; Ladanyi, Mark; Kurland, Brenda F.; Kugler, Kelly; Minna, John D... Journal: Cancer Issue: Volume 121:Issue 3(2015) Page Start: 448 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Issue 25 (1st September 2021) Authors: Drilon, Alexander; Duruisseaux, Michael; Han, Ji-Youn; Ito, Masaoki; Falcon, Christina; Yang, Soo-Ryum; Murciano-Goroff, Yonina R.; Chen, Haiquan; Okada, Morihito; Molina, Miguel Angel; Wislez, Marie; Brun, Philippe; Dupont, Clarisse; Branden, Eva; Rossi, Giulio; Schrock, Alexa; Ali, Siraj; Gouna... Journal: Journal of clinical oncology Issue: Volume 39:Issue 25(2021) Page Start: 2791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. (November 2017) Authors: Horn, Leora; Gettinger, Scott; Camidge, D. Ross; Smit, Egbert F.; Janjigian, Yelena Y.; Miller, Vincent A.; Pao, William; Freiwald, Matthias; Fan, Jean; Wang, Bushi; Chand, Vikram K.; Groen, Harry J.M. Journal: Lung cancer Issue: Volume 113(2017) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer. (1st January 2021) Authors: Smare, Caitlin; Dave, Kiran; Juarez-Garcia, Ariadna; Abraham, Pranav; Penrod, John R.; Camidge, D. Ross; Yuan, Yong Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 1124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer. Issue 8 (20th December 2012) Authors: Weickhardt, Andrew J.; Aisner, Dara L.; Franklin, Wilbur A.; Varella‐Garcia, Marileila; Doebele, Robert C.; Camidge, D. Ross Journal: Cancer Issue: Volume 119:Issue 8(2013) Page Start: 1467 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer. Issue 8 (20th December 2012) Authors: Weickhardt, Andrew J.; Aisner, Dara L.; Franklin, Wilbur A.; Varella‐Garcia, Marileila; Doebele, Robert C.; Camidge, D. Ross Journal: Cancer Issue: Volume 119:Issue 8(2013) Page Start: 1467 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗